Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering ...

Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Shares of Novo Nordisk A/S (NVO) climbed 0.4% on Monday and rose in extended trading after the Danish drugmaker said it had ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Which European healthcare stocks are most attractive right now? Seeking Alpha analysts offer their picks. Read more here.

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...